ReviewFrontiers in immunology2022
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- A systematic review of gastritis as an immune-related adverse event in clinical interventions.Human vaccines & immunotherapeutics · 2024Pooled it
- HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer.European journal of nuclear medicine and molecular imaging · 2025Trial
- Neuro-visceral immunometabolic network phenotyping via baseline whole-body [¹⁸F]FDG PET/CT underlying pathologic response to neoadjuvant immunochemotherapy in resectable NSCLC.European journal of nuclear medicine and molecular imaging · 2026Article
- Optimizing acquisition time and injected dose inBMC medical informatics and decision making · 2026Article
- Myokine-mediated mechanisms of immune checkpoint inhibitors-associated colorectal injury and repair in rectal cancer.Frontiers in immunology · 2026Review
- Imaging Immunotherapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Material-based neuroimaging and biomarker detection for central nervous system disorder.Materials today. Bio · 2025Review
- Assessment of tertiary lymphoid structures viaCancer immunology, immunotherapy : CII · 2025Article
- Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets.MedComm · 2025Review
- Molecular MRI of T-cell immune response to cryoablation in immunologically hotJHEP reports : innovation in hepatology · 2025Article
- Prediction of pathological response to neoadjuvant immunochemotherapy with baseline and post-treatmentBMC cancer · 2025Article
- Current status and future prospects of molecular imaging in targeting the tumor immune microenvironment.Frontiers in immunology · 2025Review
- Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) withEuropean journal of nuclear medicine and molecular imaging · 2024Article
- IsCancers · 2024Review
- The development process of 'fit-for-purpose' imaging biomarkers to characterize the tumor microenvironment.Frontiers in medicine · 2024Review
- Innovative applications and future trends of multiparametric PET in the assessment of immunotherapy efficacy.Frontiers in oncology · 2024Review
- Gold nanorods with iron oxide dual-modal bioprobes in SERS-MRI enable accurate programmed cell death ligand-1 expression detection in triple-negative breast cancer.APL bioengineering · 2023Article
- Synthesis and Evaluation of Fluorine-18-Labeled L-Rhamnose Derivatives.Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy, especially immune-checkpoint inhibitors (ICIs), has paved a new way for the treatment of many types of malignancies, particularly advanced-stage cancers. Accumulating evidence suggests that as a molecular imaging modality, positron emission tomography/computed tomography (PET/CT) can play a vital role in the management of ICIs therapy by using different molecular probes and metabolic parameters. In this review, we will provide a comprehensive overview of the clinical data to support the importance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.